Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis
Journal of Clinical Medicine · 21.04.2023 · 12 (8) · 3046
DOI: 10.3390/jcm12083046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.04.2023. Verfasst von Eiki Sugimoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Systemic inflammation plays a central role in the pathophysiology of psoriasis. This study examined accessible systemic inflammatory markers in patients with psoriasis vulgaris and psoriatic arthritis. We aimed to evaluate their association with psoriasis severity, the presence of arthritis, and drug continuation rates. The findings revealed that neutrophil, monocyte, and platelet count, neutrophil/lymphocyte ratio, monocyte/lymphocyte ratio, systemic inflammation response index, systemic immune/inflammation index (SII), and CRP were positively correlated with Psoriasis Area and Severity Index scores. Patients presenting with higher platelet/lymphocyte ratio (PLR) or CRP values were more likely to be diagnosed with psoriatic arthritis than with psoriasis vulgaris in the multivariate regression analysis. Importantly, patients with higher pretreatment neutrophil or platelet count, PLR, and SII were associated with lower treatment continuation rates of conventional systemic agents. Higher pretreatment scores of systemic inflammatory markers did not affect treatment retention rates of biologics. These findings suggest that several accessible systemic inflammatory markers may effectively assess underlying systemic inflammation and may provide an indication for a therapeutic approach in patients with psoriasis vulgaris and psoriatic arthritis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Zitieren
APA
Sugimoto, E., Matsuda, H., Shibata, S., Mizuno, Y., Koyama, A., Li, L., Taira, H., Ito, Y., Awaji, K., Yamashita, T., & Sato, S. (2023). Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis. Journal of Clinical Medicine, 12(8), 3046. https://doi.org/10.3390/jcm12083046
Vancouver
Sugimoto E, Matsuda H, Shibata S, Mizuno Y, Koyama A, Li L, et al. Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis. Journal of Clinical Medicine. 2023;12(8):3046. doi:10.3390/jcm12083046
BibTeX
@article{Sugimoto2023,
author = {Sugimoto, Eiki and Matsuda, Hiroki and Shibata, Sayaka and Mizuno, Yuka and Koyama, Asumi and Li, Lixin and Taira, Haruka and Ito, Yukiko and Awaji, Kentaro and Yamashita, Takashi and Sato, Shinichi},
title = {Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {8},
pages = {3046},
doi = {10.3390/jcm12083046}
}
EUVIMED